Multiple Manufacturers

FULPHILA

Manufacturer:

Multiple Manufacturers

Fulphila HCPCS:

Q5108

HCPCS Code Descriptor:

Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg

Category:

Q Code

Fulphila NDCs:

67457-0833-06, 83257-0005-41

Primary Type:

Oncology Biosimilar Colony Stimulating Factor

Generic/Specialty Status:

Multi-Source

Package Type:

Syringe

Route of Administration:

Subcutaneous

Fulphila CPT Codes:

Potential CPT administration codes for Fulphila can be found at the following link.

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

67457-0833-06

About Fulphila:

FULPHILA is a medication manufactured by multiple manufacturers and aligned to the Q Code: Q5108. FULPHILA is administered via the subcutaneous route of administration.

Fulphila (pegfilgrastim) is used to prevent patients from developing a deficiency of certain white blood cells by aiding in the production of these white blood cells. This medication is manufactured by Mylan Institutional and is a biosimilar to the drug Neulasta (J2506). Patient assistance programs for this medication can be found through the Viatris Patient Assistance program.

ACCESS PRICING AND MORE BY REGISTERING

Q5108 Added Date:

October 1, 2018

Q5108 Effective Date:

April 1, 2023

Q5108 Termination Date:

HCPCS Active

Fulphila billing and coding information can be found through Mylan at the link below:
Fulphila patient assistance information can be found through Viatris Patient Assistance Program at the URL: https://www.viatris.com/en-us/lm/united-states/patient-assistance-program
FULPHILA prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date.
Our team has not yet identified a source of side effects information for FULPHILA. Please check back in a few weeks.